How I've worked to keep hope alive throughout my CF and transplant journey Written by Lara Govendo I’m no stranger to frigid temperatures and dark days, as it often feels like the tundra here in Vermont. As we approach the winter solstice , I’m reflecting on the symbolism of letting the light in after dark times. I was born in the wee hours of Dec. 22, just as we in the northern hemisphere are emerging from the darkest day of the year and tiptoeing toward lighter days. My jo

Phase 1 trial data also indicate prolonged exposure of drug to lungs Written by Steve Bryson, PhD | ETD001,  Enterprise Therapeutics ’ inhaled investigational therapy to improve mucus clearance in people with cystic fibrosis (CF) — regardless of the underlying CF-causing mutation — was well tolerated in healthy individuals at doses higher than those predicted to be therapeutic, a study showed. The now-complete Phase 1 safety study (NCT04926701) also showed the inhaled drug

Ciske, David J. Haavisto, Amy MD Laxova, Anita Rock, Lan ZengMichael MD Farrell, Philip M. MD, PhD Author information From the Department of Pediatrics, University of Wisconsin, Madison, Wisconsin.Received for publication Dec 14, 999; accepted Jul 31, 2000. Reprint requests to (P.M.F.) University of Wisconsin Medical School, Room 1217 Medical Sciences Center, 1300 University Ave, Madison, WI 53706. E-mail: pmfarrel@facstaff.wisc.edu Pediatrics 107(4):p 699-705, April 2001 AB

New findings explain wide variability in therapy's effects among CF patients by Marisa Wexler, MS People with cystic fibrosis  (CF) who have certain lung structure abnormalities — ones visible on CT scans — are more likely than those with other issues also seen via imaging to experience improvements in lung function after starting treatment with  Trikafta . That’s according to the results of a new analysis that used imaging scans and artificial intelligence (AI) tools to asse

Adults not eligible for approved therapy report conflicting emotions by Steve Bryson, PhD | Adults with cystic fibrosis  (CF) who are not eligible for Kaftrio  therapy reported feeling forgotten in both the media and research, with conflicting emotions about those who do benefit from the approved treatment, according to a new interview-based study by researchers in the U.K. Study participants noted that they also felt a loss of hope when they realized they weren’t eligible f

Written by RTTNews.com for RTTNews (RTTNews) - BiomX Inc. (PHGE), a clinical stage biopharmaceutical company, announced that an independent Data Monitoring Committee has completed a safety review of adverse events reported in its Phase 2b trial of BX004 in cystic fibrosis. The independent Data Monitoring Committee has recommended that the study continue with revised dosing. Accordingly, the study protocol will be updated, and topline results are now expected in Q2 2026. BX00

Tobramycin inhalation solution offers affordable option to patients 6 and older by Marisa Wexler, MS The U.S. Food and Drug Administration (FDA) has approved a new generic form of inhaled tobramycin , an antibiotic that’s used to treat bacterial lung infections in people with cystic fibrosis  (CF). The newly approved therapy, tobramycin inhalation solution, will be sold by The Ritedose Corporation through its generics division, Ritedose Pharmaceuticals. It is indicated to tr

Experimental compound 3b addresses disease itself, viral threats by Michela Luciano, PhD | Researchers in Italy have developed a new experimental compound called 3b, which has shown early promise as a dual-action therapy for cystic fibrosis (CF). It addresses the dysfunction of the CFTR protein that causes the disease, as well as protects against viral threats that can worsen lung problems. In lab tests, compound 3b restored CFTR activity, blocked the growth of several resp

Study shows children with chronic conditions may face higher risk of food insecurity A recent Michigan Medicine-led study finds a link...

Story by TipRanks European Auto-Generated Newsdesk https://www.tipranks.com/news/company-announcements/softox-solutions-advances-cystic-f...